NASDAQ:SLS SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis $11.63 -0.11 (-0.94%) Closing price 10/5/2026 04:00 PM EasternExtended Trading$11.48 -0.15 (-1.29%) As of 04:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About SELLAS Life Sciences Group Stock (NASDAQ:SLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SLS alerts:Sign Up Key Stats Today's Range$11.35▼$11.7750-Day Range$10.01▼$15.4652-Week Range$1.39▼$15.88Volume4.51 million shsAverage Volume6.09 million shsMarket Capitalization$2.35 billionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs. SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer. The company has been evaluating GPS primarily in acute myeloid leukemia, including in the Phase 3 REGAL clinical trial for patients with relapsed or refractory disease. The company is also developing SLS009, a selective cyclin-dependent kinase 9 (CDK9) inhibitor being studied in oncology indications, including acute myeloid leukemia and certain solid tumors. SELLAS conducts clinical development activities through collaborations and research programs intended to support the advancement of its pipeline in the United States and other markets. The company was formerly known as Galena Biopharma, Inc. and is led by President and Chief Executive Officer Angelos Stergiou, M.D., Sc.D.AI Generated. May Contain Errors. Read More SELLAS Life Sciences Group Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks11th Percentile Overall ScoreSLS MarketRank™: SELLAS Life Sciences Group scored higher than 11% of companies evaluated by MarketBeat, and ranked 842nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingHold Consensus RatingSELLAS Life Sciences Group has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Downside RiskSELLAS Life Sciences Group has a consensus price target of $10.00, representing about 14.0% downside from its current price of $11.63.Amount of Analyst CoverageSELLAS Life Sciences Group has only been the subject of 2 research reports in the past 90 days.Read more about SELLAS Life Sciences Group's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of SELLAS Life Sciences Group is -55.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of SELLAS Life Sciences Group is -55.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSELLAS Life Sciences Group has a P/B Ratio of 25.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about SELLAS Life Sciences Group's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted29.63% of the float of SELLAS Life Sciences Group has been sold short.Short Interest Ratio / Days to CoverSELLAS Life Sciences Group has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in SELLAS Life Sciences Group has recently increased by 1.97%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSELLAS Life Sciences Group does not currently pay a dividend.Dividend GrowthSELLAS Life Sciences Group does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.26 News SentimentSELLAS Life Sciences Group has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for SELLAS Life Sciences Group this week, compared to 4 articles on an average week.Search Interest29 people have searched for SLS on MarketBeat in the last 30 days. This is an increase of 16% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added SELLAS Life Sciences Group to their MarketBeat watchlist in the last 30 days. This is a decrease of -6% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, SELLAS Life Sciences Group insiders have not sold or bought any company stock.Percentage Held by Insiders1.30% of the stock of SELLAS Life Sciences Group is held by insiders.Percentage Held by Institutions17.38% of the stock of SELLAS Life Sciences Group is held by institutions.Read more about SELLAS Life Sciences Group's insider trading history. Receive SLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLS Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSOctober 1, 2026 | prnewswire.comDespite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3September 30, 2026 | insidermonkey.comThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tariff-driven supply chain shocks continue to build beneath market headlines. Parkview Capital's new Market Crash Survival Guide breaks down what's happening under the surface and how investors are positioning their retirement savings in response. | Parkview Capital Group (Ad)Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?September 30, 2026 | finance.yahoo.comSELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer DataSeptember 30, 2026 | finance.yahoo.comSELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic DataSeptember 30, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSSeptember 29, 2026 | globenewswire.comSELLAS Life Sciences präsentiert auf der AACR-Konferenz 2026 zu Bauchspeicheldrüsenkrebs präklinische Daten zur Wirksamkeit von SLS009 in PankreaskrebsmodellenSeptember 26, 2026 | de.marketscreener.comDSee More Headlines SLS Stock Analysis - Frequently Asked Questions How have SLS shares performed this year? SELLAS Life Sciences Group's stock was trading at $3.77 at the beginning of 2026. Since then, SLS stock has increased by 208.5% and is now trading at $11.63. How were SELLAS Life Sciences Group's earnings last quarter? SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its earnings results on Tuesday, August, 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. When did SELLAS Life Sciences Group's stock split? SELLAS Life Sciences Group's stock reverse split on Friday, November 8th 2019.The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of SELLAS Life Sciences Group? Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SELLAS Life Sciences Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that SELLAS Life Sciences Group investors own include Amgen (AMGN), Generex Biotechnology (GNBT), Salesforce (CRM), Bank of America (BAC), Bristol Myers Squibb (BMY) and AbbVie (ABBV). Company Calendar Last Earnings8/11/2026Today10/06/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SLS's financial health is in the Green zone, according to TradeSmith. SLS has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SLS CIK1390478 Webwww.sellaslifesciences.com Phone(646) 200-5278Fax441-400-2875Employees13Year Founded2006Price Target and Rating Average Price Target for SELLAS Life Sciences Group$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside-14.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.91% Return on Assets-33.34% Debt Debt-to-Equity RatioN/A Current Ratio18.83 Quick Ratio18.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book25.28Miscellaneous Outstanding Shares201,950,000Free Float199,321,000Market Cap$2.35 billion OptionableNot Optionable Beta2.56 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SLS) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersThey're not telling you how bad this could getValuations have reached levels seen only a handful of times in the past century, while debt concerns and tarif...Parkview Capital Group | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis smart glasses tech is bringing the screen to your eyesGlobal AI smart-glasses shipments surged 263% in the first half of 2026, and Citi projects the market could re...The Tomorrow Investor | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy next big call (under $1)Bitcoin is trading near $80,000. For your Bitcoin position to double from here, roughly $1.5 trillion in new m...Crypto 101 Media | SponsoredMAJOR BUY ALERT: Elon, Data Centers, SpaceStock picker Luke Lango recently toured Vegas and counted more than 60 new data centers under construction, ev...InvestorPlace | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
